August M&A roundup: Trillium's redemption and Reebok's $2.5B sale

The unofficial end of summer is upon us. Some major deals rounded out the summer, including Pfizer's acquisition of Trillium Therapeutics' at a 200% premium. Trillium went from being at risk of getting delisted from the Nasdaq to being bought by one of the biggest pharmaceutical giants. While you're reading about the chunk of change involved in the Trillium sale, scroll through the rest of our highlights of the local M&A news that made the BostInno Beat newsletter in August. Stay on top of who's…